Biomimetics for treating biofilm-embedded infections

Award Information
Agency: Department of Defense
Branch: Army
Contract: W911NF-09-C-0093
Agency Tracking Number: A09A-004-0108
Amount: $100,000.00
Phase: Phase I
Program: STTR
Awards Year: 2009
Solitcitation Year: 2009
Solitcitation Topic Code: A09A-T004
Solitcitation Number: 2009.A
Small Business Information
PolyMedix, Inc.
170 N. Radnor-Chester Road, Suite 300, Radnor, PA, 19087
Duns: 621470033
Hubzone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Richard Scott
 VP Research, PolyMedix
 (484) 598-2336
Business Contact
 Dawn Eringis
Title: Director, Scientific Affairs
Phone: (484) 598-2334
Research Institution
 University of Massachusetts, Amherst
 Carol Sprague
 Office of Grant and Contract A
70 Butterfield Terrace
Amherst, MA, 1003 -9242
 (413) 545-0698
 Nonprofit college or university
Multi-drug resistant (MDR) biofilms are perhaps the most difficult bacterial infections to fight. They require novel antibiotics that operate through new mechanisms which overcome the biofilm environment. We have discovered a class of antibiotics that are novel and have new targets which appear to evade resistance development. One example is already in the clinic to systemically treat Staphyloccal infections, including methicillin-resistant S. aureus. In addition, we have shown compounds in this series are active against bacterial and fungal biofilms. This STTR aims to identify a number of lead candidates with single micromolar activity against A. baumanni, S. epidermidis, E. faecalis, P. aeruginosa, E. coli and their drug/multi-drug resistance strains in Phase I. Active compounds that meet criteria for further evaluation (including those that have been shown previously to be active against drug-resistant S. aureus) will then be tested and optimized in Phase II to treat MDR biofilm infections.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government